Pharma giant Novo Nordisk, which makes the obesity drug Wegovy, says the widespread availability of copycat medications is hurting its sales.

Omada Health is joining forces with CVS Health's Caremark as part of the pharmacy benefit manager's weight management program ...

The drug has been approved to help treat type-2 diabetes, but a new study shows an increase in use in people with type-1 diabetes, and it may not be safe.

Novo Nordisk has licensed an oral obesity drug that works via an uncommon mechanism and may help patients maintain their ...

As a diabetes medication, GLP-1s are able to treat insulin resistance, something that many people with PCOS deal with. “It’s ...

Investors who jumped on the Hims & Hers Health (NYSE: HIMS) bandwagon have experienced this pain first-hand. Shares of the health and wellness platform operator skyrocketed more than 670% between Jan.

Anecdotal reports suggest drugs like Ozempic may curb not just appetite but also impulsive or addictive behaviour, hinting at ...

Explore what to expect now that the Hims & Hers stock price now that it has crashed hard in the past few weeks.

Billions of dollars in annual revenue and the health of millions of patients are at stake in a drug industry battle over who ...

In contrast, Eli Lilly (NYSE: LLY) and Hims & Hers Health (NYSE: HIMS) both jumped on today's news. They rose 2.7% and 7%, ...

GLP-1 weight loss drugs cost CT’s Medicaid program $85 million in FY 2024, 35% of annual Medicaid pharmaceutical budget ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...